Herpes Zoster Infections News

FDA Approves Shingles Vaccine With More Than 90% Efficacy - Managed Care magazine



Medscape
 
FDA Approves Shingles Vaccine With More Than 90% Efficacy 
Managed Care magazine
Zoster vaccine recombinant, adjuvanted (Shingrix, GlaxoSmithKline) is a non-live, recombinant subunit vaccine given intramuscularly in two doses for the prevention of herpes zoster in adults 50 years of age and older. ?The risk and severity of shingles ...
FDA approves shingles vaccine Shingrix Healio
Agenus (AGEN) Granted FDA Approval for GlaxoSmithKline (GSK) Shingles Vaccine with Agenus' QS-21 Stimulon ... StreetInsider.com
FDA Clears Shingles Vaccine Shingrix for Adults 50 and Older Medscape
PMLiVE  -Contagionlive.com  -The Wall Street Transcript 
all 40 news articles » 


New Report Examines the Growth of Herpes Zoster Infection Treatment Market Forecast to 2025 - Medgadget (blog)



New Report Examines the Growth of Herpes Zoster Infection Treatment Market Forecast to 2025 
Medgadget (blog)
Herpes Zoster (shingles) is a cutaneous, acute viral infection caused by the varicella-zoster virus. Herpes Zoster is the outbreak of rash on the skin that cause burning and pain. Herpes Zoster is caused by the same virus which cause chickenpox. The ...

and more » 


FDA approves a new vaccine for shingles that provides broad protection - STAT



STAT
 
FDA approves a new vaccine for shingles that provides broad protection 
STAT
Shingles is a delayed complication of chickenpox, a highly infectious disease most children suffered through in the era before the chickenpox vaccine was developed. People who have had chickenpox harbor the varicella zoster virus ? the bug that causes ...
Shingrix approved in the US for prevention of shingles in adults aged 50 and over Markets Insider
FDA Approves GSK's Shingles Vaccine with Agenus' QS-21 Stimulon® Adjuvant PR Newswire (press release)
A second approval for Shingrix, now in the world's largest market The Pharma Letter
MD Magazine 
all 39 news articles » 


Herpes Zoster Pipeline Market (Shingles) H2 2017 Analysis, Drug Profile, Development Stages - Medgadget (blog)



Herpes Zoster Pipeline Market (Shingles) H2 2017 Analysis, Drug Profile, Development Stages 
Medgadget (blog)
The latest Pharmaceutical and Healthcare disease pipeline guide Herpes Zoster (Shingles) ? Pipeline Review, H2 2017, provides an overview of the Herpes Zoster Pipeline Market (Shingles) (Infectious Disease) landscape. Shingles (herpes zoster) is a ...

 


Zostavax Vaccine Efficacy: A 12-Year Review - Monthly Prescribing Reference



Zostavax Vaccine Efficacy: A 12-Year Review 
Monthly Prescribing Reference
... experts from the Centers for Disease Control and Prevention (CDC) and Marshfield Clinic Research Institute presented findings from a systematic review of the duration of efficacy of Zostavax (zoster vaccine live [ZVL]; Merck) against herpes zoster ...

 


GSK Shingles Vaccine Shingrix Gets First Okay in Canada - Medscape



Medscape
 
GSK Shingles Vaccine Shingrix Gets First Okay in Canada 
Medscape
GlaxoSmithKline's recombinant zoster vaccine (adjuvanted) (Shingrix) has been approved in Canada for the prevention of herpes zoster (shingles) in people aged 50 years and older. "The vaccine combines an antigen, glycoprotein E, and an adjuvant system ...
SHINGRIX approved in Canada as the first non-live adjuvanted vaccine to help protect against shingles Markets Insider

all 5 news articles » 


Binding Site Offers Varicella Zoster Virus (VZV) Antigens for IVD Manufacturing & Research Applications - Lab Manager Magazine



Lab Manager Magazine
 
Binding Site Offers Varicella Zoster Virus (VZV) Antigens for IVD Manufacturing & Research Applications 
Lab Manager Magazine
VZV is one of eight herpes viruses known to infect humans. VZV infections are species-specific to humans and causes chickenpox (varicella), a disease most commonly affecting children, teens, and young adults, as well as herpes zoster in older adults ...

 


NanoViricides to Present Results On Successful Treatment Of ... - PR Newswire (press release)



NanoViricides to Present Results On Successful Treatment Of ... 
PR Newswire (press release)
SHELTON, Conn., Oct. 17, 2017 /PRNewswire/ -- NanoViricides, Inc. (NYSE American: NNVC) (the "Company") will present the results of its anti-herpes ...

and more » 


Recent Anti-Infective Trials Reviewed at ID Week 2017 - Contagionlive.com



Contagionlive.com
 
Recent Anti-Infective Trials Reviewed at ID Week 2017 
Contagionlive.com
Francisco Marty, MD, Division of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts, reviewed recent antiviral trials, excepting those involving HIV. His focus was the herpes zoster subunit vaccine, intravenous (IV) influenza ...

 


GSK's Shingles Vaccine Approved in Canada | BioPharm International - BioPharm International



GSK's Shingles Vaccine Approved in Canada | BioPharm International 
BioPharm International
The vaccine is a non-live, recombinant subunit vaccine that combines an antigen and an adjuvant system to trigger a targeted and long-lasting immune ...

and more »